Ameriprise’s Marker Therapeutics MRKR Stock Holding History

Ameriprise’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,066	Closed	-$54K	–	3742
2019 Q3	$54K	Buy	+1,066	New	+$63K	﹤0.01%	3665
2019 Q1	–	Sell	-250	Closed	-$14K	–	3742
2018 Q4	$14K	Buy	+250	New	+$18.2K	﹤0.01%	3600

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Ameriprise's MRKR Position: Q4 2019 in Review

Ameriprise sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 1,066 shares — an estimated $54K sold.

Ameriprise first reported a position in MRKR in Q4 2018 and held it in 2 quarters. The position peaked at $54K in Q3 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

Ameriprise reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
Ameriprise sold 1,066 Marker Therapeutics shares in Q4 2019, an estimated $54K.
Ameriprise first reported a position in Marker Therapeutics in Q4 2018 and held it in 2 quarters.
Ameriprise's Marker Therapeutics position peaked at $54K in Q3 2019.
65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Ameriprise's 13F filing for Q4 2019, filed 14 Feb 2020.